Company intelligence / Profile preview

SciMeDent Health

Jericho, New York, United States

Ownership: Private
Development stage: Other

Overview

SciMeDent signed a definitive sublicense agreement in August 2010 with Genesis Biopharma for development of a peptidomimetic compound for treating Painful Diabetic Neuropathy. The company planned to conduct Phase 1A studies with $800,000 in funding. However, the sublicense agreement was terminated subsequent to September 30, 2010.

Therapeutic areas: Neurology
Modalities: Peptides
Industry: Biotech

Partnerships

Genesis Biopharma, Inc. (Montreal-based; sublicense agreement signed August 9, 2010, but subsequently terminated)

Beyond the preview

Go deeper on SciMeDent Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SciMeDent Health.

Explore the full profile